Status:
UNKNOWN
EGFR-targeted Therapy for Gastric Cancer
Lead Sponsor:
National Cancer Center, Korea
Collaborating Sponsors:
Korean Cancer Study Group
Conditions:
Adenocarcinoma of the Stomach
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line...
Detailed Description
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining
Eligibility Criteria
Inclusion
- Key inclusion criteria
- Histologically-proven gastric and gastroesophageal junction adenocarcinoma
- Refractory to first-line chemotherapy for metastatic disease
- Presence of at least 1 measurable lesion according to RECIST version 1.1
- EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining
- Key exclusion criteria
- Prior exposure to taxane or EGFR-targeted therapy
Exclusion
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04077255
Start Date
September 1 2019
End Date
December 31 2023
Last Update
November 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea, 10408